Neng Wang
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- Biomaterials top 1%
- Advanced Cellulose Research Studies
Papers in
- Hepatology 10
- Hepatocellular Carcinoma Treatment and Prognosis 8
- Pharmacology 10
- Co-authors
- Zhiyu WangEnyong DingRongshi ChengShengqi WangYifeng ZhengFengxue ZhangJiangang ShenXiaoming Xie
- Journals
- Frontiers in Pharmacology (6 papers)Oncotarget (6 papers)Cell Death and Disease (5 papers)Phytomedicine (4 papers)Frontiers in Oncology (4 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Neng Wang
127 papers receiving 5.7k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Cancer Research 1.0k
- Biomaterials 754
- Pharmacology 490
- Oncology 1.1k
- Hepatology 313
Countries citing papers authored by Neng Wang
This map shows the geographic impact of Neng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neng Wang more than expected).
Fields of papers citing papers by Neng Wang
This network shows the impact of papers produced by Neng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neng Wang. The network helps show where Neng Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Neng Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 15 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 16 | |
| 6 | 2024 | 2 | |
| 7 | 2023 | 19 | |
| 8 | 2023 | 5 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 16 | |
| 11 | 2023 | 13 | |
| 12 | 2023 | 30 | |
| 13 | 2022 | 10 | |
| 14 | 2022 | 6 | |
| 15 | 2022 | 2 | |
| 16 | 2021 | 18 | |
| 17 | 2021 | 52 | |
| 18 | 2017 | 58 | |
| 19 | 2012 | 50 | |
| 20 | Choosing of Supplier for Green Manufacturing | 2001 | 2 |
About Neng Wang
Neng Wang is a scholar working on Hepatology, Pharmacology, Molecular Biology, Oncology and Cancer Research, having authored 135 papers that have together received 5.8k indexed citations. Recurring topics across this work include Immune cells in cancer (12 papers), Caveolin-1 and cellular processes (9 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Autophagy in Disease and Therapy (8 papers), Liver Disease Diagnosis and Treatment (7 papers), Bioactive Natural Diterpenoids Research (6 papers), Cancer, Stress, Anesthesia, and Immune Response (6 papers) and MicroRNA in disease regulation (6 papers). The work is most often cited by research in Cancer Research (1.0k citations), Biomaterials (754 citations), Pharmacology (490 citations), Oncology (1.1k citations) and Hepatology (313 citations). Neng Wang has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Zhiyu Wang, Enyong Ding, Rongshi Cheng, Shengqi Wang, Yifeng Zheng, Fengxue Zhang, Jiangang Shen, Xiaoming Xie, Xuan Wang and Bowen Yang. Their work appears in journals such as Frontiers in Pharmacology, Oncotarget, Cell Death and Disease, Phytomedicine and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.